Advertisement
U.S. markets closed

AtriCure, Inc. (ATRC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
31.94-0.20 (-0.62%)
At close: 04:00PM EDT
31.94 0.00 (0.00%)
After hours: 05:39PM EDT

AtriCure, Inc.

7555 Innovation Way
Mason, OH 45040
United States
513 755 4100
https://www.atricure.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full Time Employees1,200

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael H. CarrelCEO, President & Director1.62MN/A1971
Ms. Angela L. Wirick CPAChief Financial Officer668.62kN/A1978
Mr. Douglas J. SeithChief Operating Officer989.17kN/A1966
Mr. Justin J. NozneskyChief Marketing & Strategy Officer644.73kN/A1978
Ms. Deborah YountChief Human Resources Officer498.36kN/A1966
Mr. Salvatore Privitera J.D.Chief Technical Officer471.15kN/A1967
Dr. Vinayak Doraiswamy Ph.D.Chief Scientific Officer777.66kN/A1972
Mr. Karl S. Dahlquist CCEP, J.D.Chief Legal OfficerN/AN/A1970
Valerie Storch-WillhausVice President of Corporate Marketing & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Corporate Governance

AtriCure, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 2. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.